Vector Science and Therapeutics Corp. Welcomes Angus Jackson as Managing Director of Corporate Development

Vector Science and Therapeutics Corp. Enhances Leadership with Angus Jackson's Appointment

Vector Science and Therapeutics Corp. has recently made headlines with the strategic appointment of Angus Jackson as the new Managing Director of Corporate Development. This move comes at a crucial time as the company aims to bolster its presence in the life sciences and therapeutics sectors. In his new role, Mr. Jackson will spearhead both organic and inorganic growth initiatives, focusing on strategic partnerships, acquisition evaluation, and long-term commercial development strategies.

Mr. Jackson brings a wealth of experience to the table, with a multidisciplinary background that includes investment banking, corporate law, and operational expertise in the life sciences field. Prior to joining Vector, he worked as an investment banker at Outcome Capital, a boutique firm based in Boston, specializing in healthcare and life sciences. There, he provided advisory services across various segments, including pharmaceuticals and medical technology, facilitating mergers, acquisitions, and capital-raising initiatives.

Before his tenure in investment banking, Mr. Jackson played a significant role in a family-owned contract manufacturing business, which served the pharmaceutical industry. His hands-on experience in corporate development and operational responsibilities will be invaluable to Vector as it seeks to explore strategic initiatives and acquisition opportunities.

Strategic Vision and Long-Term Goals

Angus Jackson’s extensive transaction execution experience and direct industry exposure position him uniquely to identify growth opportunities across Vector's various business and technology platforms. His primary focus will be on commercial expansion and developing strategic alliances that complement Vector's existing capabilities, particularly in the areas of drug delivery technologies and peptide-related offerings.

“I am looking forward to joining Vector at such an important stage in its evolution,” said Mr. Jackson. “We have the opportunity to build on existing technologies and deepen our strategic partnerships, helping Vector to explore new avenues for commercial growth.”

The company’s leadership expressed strong confidence in Mr. Jackson's capabilities. Tommy Thompson, Chairman of Vector Science and Therapeutics, remarked that “disciplined corporate development is essential to turning Vector's technology platforms into lasting commercial value.” He emphasized Mr. Jackson's background in healthcare investment banking and law, stating that it equips the company to rigorously evaluate and execute strategic opportunities.

Russell Starr, President of Vector Science and Therapeutics, added, “Angus brings a unique blend of transaction experience and practical knowledge of pharmaceutical manufacturing, which is crucial as we scale our operations.” He believes that Mr. Jackson's skills in identifying and executing the right acquisition and partnership opportunities will be key to driving the company’s growth and providing value to shareholders.

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. is a forward-thinking medical technology company that is revolutionizing drug delivery technology and pharma-grade peptide manufacturing. The company focuses on various medical applications, including sports medicine, pain management, and regenerative medicine. Unlike conventional research-grade materials, Vector's peptides are pharma-grade and produced under stringent cGMP, FDA, and ISO-compliant conditions, ensuring high-quality standards are met.

As Vector continues to advance its current platforms and explore new growth opportunities, Angus Jackson's appointment signals a strong commitment to expanding its market reach and developing cutting-edge therapeutic solutions. For more information about the company, you can visit their official website at vectorscience.co.